Z-VAD-FMK, inhibitor

Z-VAD-FMK

Cat. Num. AAA578589

• Purity: 99.41%
• Synonyms: Z-VAD-FMK; inhibitor

• Purity/Purification: 99.41%
• Form/Format: Solid

• CAS: 187389-52-2
• Solubility: DMSO: 93mg/ml (198.93mM); Ethanol: <1mg/ml; Water: <1mg/ml
• Animal Model: Mice
• Analytical Data: HNMR and HPLC: Consistent with Structure
• Formula: C22H30FN3O7
• Preparing Stock Solutions: 1mg;5mg;10mg; 1mM; 2.139mL; 10.695mL; 21.391mL; 5mM; 0.428mL; 2.139mL; 4.278mL; 10mM; 0.214mL; 1.07mL; 2.139mL; 50mM; 0.043mL; 0.214mL; 0.428mL; *Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents.; The storage conditions and period of the stock solution : -80°C for 1 month. Please use it as soon as possible.
• In Vivo Activity: LPS (30 mg/kg) was administered intravenously to Institute for Cancer Research mice. Z-VAD.fmk was injected before and after the administration of LPS. The injection of Z-VAD.fmk suppressed the caspase-3 activity in lung tissues and significantly decreased the number of terminal dUTP nick-end labeling-positive cells [4]. Treatment with the specific caspase inhibitor Z-VAD-FMK (i.p.) prior to heat-killed group B streptococcus (i.p.) delayed but did not prevent preterm delivery [5]
• In vitro: In vitro Z-VAD.FMK was a poor inhibitor of PARP protease activity in cell lysates. Z-VAD.FMK (10 ?M) is a potent inhibitor of Fas-induced apoptosis [1]. CPP32 is activated during camptothecin-induced apoptosis, and Z-VAD-fmk blocks all features of apoptosis. However, Z-VAD-fmk is inactive in a cell-free system reconstituted from nuclei of untreated HL60 cells and cytosol from camptothecin-treated cells [2]. z-VAD-FMK suppressed TUNEL and caspase-3 staining in endothelial cells, decreased caspase-3 activation, reduced BBB permeability, relieved vasospasm, abolished brain edema, and improved neurological outcome [3].
• Cell Research: Z-VAD-FMK is dissolved in DMSO and stored, and then diluted with appropriate medium before use[3]. PCR productscontaining coding sequences for the dSMN (forward primer: 5'-TAA TAC GAC TCA CTA TAG GG AAG ACG TAC GAC GAGTCG-3'; and reverse primer: 5'-TAA TAC GAC TCA CTA TAG GG GTG GTG CTG GCT TCT TTC-3'; product length, 601bps;bold and italics letters represent T7 promoter sequences) and control Drosophila Presenilin (dPsn) gene (forward primer: 5'-TAA TAC GAC TCA CTA TAG GG TG GCT GCT GTC AAT CTC-3'; and reverse primer: 5'-TAA TAC GAC TCA CTA TAG GGCGA TAG CAA CGC TTC TTG-3'; product length: 543bps) are obtained and gel-purified. Double-stranded RNAs (dsRNA) aregenerated by transcription with Ribomax T7 Transcription kit and digested with Rnase-free DNase. The dsRNA products areethanol precipitated and annealed by incubation at 65°C for 30 min and then slowly allowed to cool at room temperature. Theannealed dsRNA products are analyzed on a 1% agaorse gel to ensure the majority of dsRNA existed as a single band. ThedsRNA (2 ug) and/or plasmid DNAs (2 ug) are introduced into cells by using Cellfectin. Caspase inhibition is achieved by using 50 uM of Z-VAD-FMK in the culture medium[3].
• Targets(IC50): Pan-caspase: None
• Preparation and Storage: Store at 0 to 4°C for short term (days to weeks); For long term storage, store at -20°C (months)

Structure

Test Data

Related Product Information for Z-VAD-FMK, inhibitor

Z-VAD(OMe)-FMK is a cell-permeable and irreversible pan-caspase inhibitor. It inhibits cleavage of PARP, preventing apoptosis when used at 10-50 UM.

Product Categories/Family for Z-VAD-FMK, inhibitor

Molecules; Caspase inhibitor